Mark Schoenberg Sells 4,551 Shares of UroGen Pharma Ltd. (NASDAQ:URGN) Stock

UroGen Pharma Ltd. (NASDAQ:URGN) insider Mark Schoenberg sold 4,551 shares of UroGen Pharma stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $11.14, for a total value of $50,698.14. Following the completion of the sale, the insider now owns 145,666 shares in the company, valued at approximately $1,622,719.24. This trade represents a 3.03 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

UroGen Pharma Price Performance

UroGen Pharma stock opened at $11.64 on Thursday. UroGen Pharma Ltd. has a 52 week low of $9.78 and a 52 week high of $20.70. The firm’s 50-day simple moving average is $11.10 and its 200 day simple moving average is $12.61. The company has a current ratio of 9.00, a quick ratio of 8.77 and a debt-to-equity ratio of 4.77.

UroGen Pharma (NASDAQ:URGN) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.55) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.84) by $0.29. The business had revenue of $25.20 million during the quarter, compared to analysts’ expectations of $24.22 million. During the same period last year, the company earned ($0.68) EPS. On average, equities analysts predict that UroGen Pharma Ltd. will post -3.12 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of URGN. China Universal Asset Management Co. Ltd. grew its holdings in UroGen Pharma by 90.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,100 shares of the company’s stock valued at $103,000 after buying an additional 3,856 shares during the last quarter. BNP Paribas Financial Markets lifted its position in shares of UroGen Pharma by 221.8% in the third quarter. BNP Paribas Financial Markets now owns 8,546 shares of the company’s stock valued at $109,000 after acquiring an additional 5,890 shares in the last quarter. Oppenheimer & Co. Inc. purchased a new stake in shares of UroGen Pharma in the fourth quarter valued at $126,000. Intech Investment Management LLC acquired a new stake in shares of UroGen Pharma during the third quarter valued at $155,000. Finally, Verition Fund Management LLC purchased a new stake in UroGen Pharma during the 3rd quarter worth about $168,000. 91.29% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. D. Boral Capital restated a “buy” rating and set a $25.00 target price on shares of UroGen Pharma in a research report on Thursday, January 23rd. EF Hutton Acquisition Co. I upgraded shares of UroGen Pharma to a “strong-buy” rating in a research note on Monday, October 14th. Oppenheimer restated an “outperform” rating and set a $40.00 target price on shares of UroGen Pharma in a research report on Wednesday, October 16th. Finally, HC Wainwright reiterated a “buy” rating and set a $60.00 price target on shares of UroGen Pharma in a research report on Tuesday, October 15th. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $43.70.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.